YONGCHENG SONG to Histone-Lysine N-Methyltransferase
This is a "connection" page, showing publications YONGCHENG SONG has written about Histone-Lysine N-Methyltransferase.
Connection Strength
1.070
-
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol. 2016 Mar 12; 9:24.
Score: 0.464
-
Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth. Theranostics. 2021; 11(17):8172-8184.
Score: 0.168
-
Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget. 2014 Nov 15; 5(21):10665-77.
Score: 0.106
-
An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
Score: 0.102
-
Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. J Med Chem. 2012 Sep 27; 55(18):8066-74.
Score: 0.091
-
Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J Am Chem Soc. 2011 Oct 26; 133(42):16746-9.
Score: 0.085
-
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016 08 18; 128(7):971-81.
Score: 0.030
-
DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS One. 2014; 9(5):e98270.
Score: 0.026